Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05154890 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency
A Phase 1 study, sponsored by Aeglea Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05154890: Clinical Trial Phase 1 study, sponsored by Aeglea Biotherapeutics.
NCT05154890 is a Phase 1 study that was terminated before completion, run by Aeglea Biotherapeutics. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05154890, a Phase 1 study, was terminated before completion, sponsored by Aeglea Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of pegtarviliase in approximately 36 subjects with homocystinuria due to CBS deficiency.
Primary Outcome
Incidence of treatment-emergent adverse events
Interventions
- DRUG Pegtarviliase IV
- DRUG Pegtarviliase SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 1 |
Why NCT05154890 stopped before completion
NCT05154890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Pegtarviliase IV is the first listed.
NCT05154890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05154890 about?
NCT05154890 is a clinical study titled "A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency". The purpose of this study is to evaluate the safety and tolerability of pegtarviliase in approximately 36 subjects with homocystinuria due to CBS deficiency.
What is the current status of trial NCT05154890?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-05-13. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT05154890?
The interventions under investigation include: Pegtarviliase IV (DRUG), Pegtarviliase SC (DRUG).
Who is sponsoring clinical trial NCT05154890?
This trial is sponsored by Aeglea Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05154890's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI